Dexcom officer plans sale of 3,638 shares

Dexcom officer Jereme Sylvain filed a Rule 144 notice to sell 3,638 shares of DXCM common stock with an indicated value of about $303,000.

Available on EDGAR 09/10/2026 - 04:06 PM EDT Accepted by SEC EDGAR 09/10/2026 - 04:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

DEXCOM, INC. (DXCM) received a notice of proposed sale of its common stock under Rule 144 by officer Jereme Sylvain. The filing covers 3,638 shares of common stock to be sold through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $302,936.26 as of September 10, 2026.

The shares derive from restricted stock awarded on December 15, 2023 (2,920 shares) and September 8, 2024 (718 shares), and are listed for sale on NASDAQ.

Key Figures

Shares to be sold under Rule 144: 3,638 shares Aggregate market value: $302,936.26 Restricted stock grant December 15, 2023: 2,920 shares +2 more

5 metrics

Shares to be sold under Rule 144 3,638 shares Common stock of Dexcom, Inc. covered by the notice through Morgan Stanley Smith Barney LLC

Aggregate market value $302,936.26 Indicated value for 3,638 shares of Dexcom, Inc. common stock as of September 10, 2026

Restricted stock grant December 15, 2023 2,920 shares Restricted stock of Dexcom, Inc. listed as a source of shares to be sold

Restricted stock grant September 8, 2024 718 shares Restricted stock of Dexcom, Inc. listed as a source of shares to be sold

Trading market NASDAQ Market on which Dexcom, Inc. common stock is listed for the planned sale

Key Terms

Rule 144, Restricted Stock, Issuer

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock financial

"Common | 12/15/2023 | Restricted Stock | Issuer"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Issuer financial

"Restricted Stock | Issuer | | | 2920"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for DXCM disclose?

It discloses that officer Jereme Sylvain has filed a notice under Rule 144 to sell 3,638 shares of Dexcom, Inc. common stock through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $302,936.26 as of September 10, 2026.

How many DXCM shares are covered by Jereme Sylvain’s planned Rule 144 sale?

The notice covers 3,638 shares of Dexcom, Inc. common stock. These shares correspond to 2,920 restricted shares granted on December 15, 2023 and 718 restricted shares granted on September 8, 2024.

What is the indicated dollar value of the DXCM shares in this Form 144?

The filing indicates an aggregate market value of $302,936.26 for the 3,638 shares of Dexcom, Inc. common stock covered by the planned Rule 144 sale, with NASDAQ listed as the trading market and September 10, 2026 as the reference date.

Which broker is handling the planned DXCM share sale under Rule 144?

The planned sale is listed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York. The filing identifies NASDAQ as the market on which Dexcom, Inc. common stock is traded.

What types of DXCM securities are being sold in this Form 144?

The securities are restricted stock of Dexcom, Inc., issued by the issuer on December 15, 2023 and September 8, 2024. The total number of restricted shares covered for potential sale is 3,638.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001681267
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	DEXCOM, INC.
SEC File Number	000-51222
Address of Issuer	6340 Sequence Drive San Diego CALIFORNIA 92121
Phone	(858) 200-0200
Name of Person for Whose Account the Securities are To Be Sold	JEREME SYLVAIN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	3638	302936.26	377360765	09/10/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/15/2023	Restricted Stock	Issuer			2920	12/15/2023	Not Applicable
Common	09/08/2024	Restricted Stock	Issuer			718	09/08/2024	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/10/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jereme M Sylvain
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)